公开(公告)号：US11653665B2

公开(公告)日：2023-05-23

申请号：US16997591

申请日：2020-08-19

Applicant: AMOREPACIFIC CORPORATION

Inventor： Kwanghyun Shin ,  Wonkyung Cho ,  Jinoh Chung ,  Yong Deog Hong

IPC: A23F3/32 ,  A23F3/10 ,  B01J2/16 ,  B01J2/14

CPC classification number: A23F3/32 ,  A23F3/10 ,  B01J2/14 ,  B01J2/16

Abstract: Shown are a particulate processed product of tea and a method for preparing the same. The particulate processed product of tea has a sphericity S10 value of a particle corresponding to 10% cumulative subdistribution in cumulative distribution measured for the sphericity of tea particles of 0.68 or greater. The processed product of tea is convenient to drink because it is readily wetted and dispersed in water. In addition, it can be easily packaged and used due to a low angle of repose and thus excellent flowability.

公开(公告)号：US11612172B2

公开(公告)日：2023-03-28

申请号：US16664272

申请日：2019-10-25

Applicant: AMOREPACIFIC CORPORATION

Inventor： Kwanghyun Shin ,  Wonkyung Cho ,  Jinoh Chung ,  Yong Deog Hong

IPC: A23F3/32 ,  A23F3/14 ,  A23L19/00

Abstract: The present disclosure shows a particulate processed product of tea with quick dispersibility in water and a method for manufacturing a particulate processed product of tea. The processed product of tea comprises 20% by weight or less of fine powders having a particle diameter of 75 μm or less based on the total weight of the tea particles. The manufacturing method comprises the step of manufacturing tea particles using a fluid-bed rotor granulator having a rotor disc. The processed product of tea has quick wettability and dispersibility in water and thus is easy to drink. Also, the processed product of tea has a low angle of repose and thus has excellent flowability, so that it is easy to pack and use.

公开(公告)号：US11382900B2

公开(公告)日：2022-07-12

申请号：US16805202

申请日：2020-02-28

Applicant: AMOREPACIFIC CORPORATION

Inventor： Gyeyoung Choi ,  Hyunjin Nam ,  Miyoung Park ,  Kyoungmi Jung ,  Jihae Lee ,  Chang Soon Choi ,  Youngho Park ,  Jong Hwa Roh ,  Eunsil Park ,  Jaehong Park ,  Kwanghyun Shin ,  Byoung Young Woo ,  Kiwha Lee ,  Wonkyung Cho ,  Joonho Choi

IPC: A61K31/44 ,  A61K9/00 ,  A61K9/06

Abstract: Disclosed is a method for preventing or treating sleep disorders using TRPV1 receptor antagonist, (R)—N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide. The method of the present invention can effectively and safely prevent or treat sleep disorders accompanying pruritus caused by atopic dermatitis.

公开(公告)号：US10479763B2

公开(公告)日：2019-11-19

申请号：US15325349

申请日：2016-02-15

Applicant: AMOREPACIFIC CORPORATION

Inventor： Byoung Young Woo ,  Ki-Wha Lee ,  Kwang-Hyun Shin ,  Miyoung Park ,  Kyoungmi Jung ,  Joonho Choi ,  Gyeyoung Choi ,  Wonkyung Cho ,  Young-Ho Park

IPC: C07C303/42 ,  C07C303/36 ,  C07C311/08 ,  C07C303/44 ,  C07D213/56 ,  C07B57/00 ,  C07C63/06

Abstract: The present specification relates to a chiral resolution method of a stereoisomer mixture, comprising a step of mixing a stereoisomer mixture of compounds, in which an amine group is bound to an asymmetric carbon atom, with a chiral auxiliary and salt-forming auxiliary compound, wherein the chiral auxiliary is an O,O′-diacyltartaric acid derivative, more specifically, a 2,3-dibenzoyl-tartaric acid or O,O′-di-p-toluoyl tartaric acid, the salt-forming auxiliary compound is mandelic acid or camphorsulfonic acid, and an optical isomer having a high level of optical purity can be obtained by using the method. Therefore, according to one aspect of the present invention, the method can be useful in pharmaceutical or cosmetic field when preparing an optical isomer having a high optical purity.

公开(公告)号：US11998633B2

公开(公告)日：2024-06-04

申请号：US17289382

申请日：2019-10-16

Applicant: Amorepacific Corporation

Inventor： Wonkyung Cho ,  Kwanghyun Shin ,  Joonho Choi ,  Kiwha Lee ,  Jong Hwa Roh ,  Miyoung Park ,  Youngho Park ,  Eunsil Park ,  Jaehong Park ,  Byoung Young Woo ,  Min Soo Kim ,  Eun Sol Ha

IPC: A61K9/08 ,  A61K9/06 ,  A61K31/44 ,  A61K47/10 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38 ,  A61K9/00

CPC classification number: A61K9/06 ,  A61K31/44 ,  A61K47/10 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38 ,  A61K9/0014

Abstract: One aspect of the present disclosure relates to a sol-gel composition enabling reversible sol-gel transition and, more specifically, to a sol-gel composition of which the viscosity changes by external physical force so that reversible sol-gel transition is performed.

公开(公告)号：US12059412B2

公开(公告)日：2024-08-13

申请号：US16976140

申请日：2019-03-21

Applicant: Amorepacific Corporation

Inventor： Joonho Choi ,  Wonkyung Cho ,  Jong Hwa Roh ,  Kwanghyun Shin ,  Byoung Young Woo ,  Min Soo Kim ,  Miyoung Park ,  Youngho Park ,  Eunsil Park ,  Jaehong Park ,  Kiwha Lee

IPC: A61K31/44 ,  A61K9/00 ,  A61K31/79 ,  A61K47/32

CPC classification number: A61K31/44 ,  A61K9/0014 ,  A61K47/32

Abstract: One aspect of the present disclosure relates to a pharmaceutical composition, containing (R)-N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide as a first ingredient and containing a vinylpyrrolidone-based polymer as a second ingredient. The composition of one aspect of the present disclosure has a formulation characteristic in which the crystal formation of a compound represented by chemical formula 1 is delayed for a long time.

公开(公告)号：US11878008B2

公开(公告)日：2024-01-23

申请号：US16805381

申请日：2020-02-28

Applicant: AMOREPACIFIC CORPORATION

Inventor： Gyeyoung Choi ,  Hyunjin Nam ,  Miyoung Park ,  Kyoungmi Jung ,  Jihae Lee ,  Chang Soon Choi ,  Youngho Park ,  Jong Hwa Roh ,  Eunsil Park ,  Jaehong Park ,  Kwanghyun Shin ,  Byoung Young Woo ,  Kiwha Lee ,  Wonkyung Cho ,  Joonho Choi

IPC: A61P17/04 ,  A61K31/44 ,  A61K9/00

CPC classification number: A61K31/44 ,  A61K9/0014 ,  A61P17/04

Abstract: Disclosed is a method for preventing or treating atopic dermatitis using TRPV1 receptor antagonist. More specifically, it may be possible to prevent and/or treat the atopic dermatitis without any side effects such as an increase in body temperature, epidermal atrophy, and the like by percutaneously administrating a composition for external use on the skin containing the TRPV1 receptor antagonist.